PPARG and cancer: Thiazolidinediones have been found to inhibit cancer cell behaviour in various tumour cells via PPARγ‐dependent and PPARγ‐independent mechanisms, such as a decrease of metalloproteinase 2 (MMP2) activity [9, 12, 13].